Pharma / CDMO / Clinical
Homogeneous conjugates for therapeutics and diagnostics
What we offer
- A route to precise, reproducible conjugation for therapeutic development and manufacturing.
- Site-specific enzymatic conjugation, a hydrolysis-resistant covalent bond, with quantitative yield.
- Direct access to our scientific team for feasibility studies, application development and process optimization.
- Flexible routes to project-based licensing, material supply and integration into CDMO service offerings.
How we work together
- We agree on your target construct, technical requirements and evaluation criteria, under confidentiality where appropriate.
- We design and conduct a feasibility study together, or support evaluation in your laboratory.
- We review the data and define any further development, process optimization or scale-up work required.
- We establish appropriate collaboration, supply or licensing terms as the project advances.
Learn more
More on working with Pharma / CDMO / Clinical
In therapeutic development, precise control of conjugate composition matters for product characterization, consistency and manufacturing reproducibility. Connectase enables site-specific protein modification through an enzymatic reaction that forms a stable covalent bond. This offers a promising approach for ADCs and other protein-based therapeutics where defined conjugation is important. We work with pharmaceutical developers and CDMOs to assess performance on relevant constructs, establish feasibility and adapt the process to specific development requirements. We are positioning Connectase in therapeutic development and manufacturing. We aim to work closely with partners to generate proof of concept, deliver the required quality and regulatory fit and build a pipeline of superior targeted therapeutics based on proprietary conjugation technology.